Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P < 0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (-0.8, P = 0.01) and serum concentrations of IL-6 (-0.5 pg/ml, P = 0.045) and IL-18 (-31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 microg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P < 0.001). CONCLUSIONS:
|
Authors | Katherine Esposito, Miryam Ciotola, Diego Carleo, Bruno Schisano, Franco Saccomanno, Ferdinando Carlo Sasso, Domenico Cozzolino, Roberta Assaloni, Domenico Merante, Antonio Ceriello, Dario Giugliano |
Journal | Diabetes care
(Diabetes Care)
Vol. 29
Issue 5
Pg. 1071-6
(May 2006)
ISSN: 0149-5992 [Print] United States |
PMID | 16644639
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Lipids
- Thiazolidinediones
- Rosiglitazone
|
Topics |
- Adult
- Blood Glucose
(analysis)
- Blood Pressure
- Body Size
- Double-Blind Method
- Endothelium, Vascular
(physiopathology)
- Female
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Inflammation
(physiopathology)
- Insulin
(blood)
- Lipids
(blood)
- Male
- Metabolic Syndrome
(drug therapy, physiopathology)
- Middle Aged
- Rosiglitazone
- Thiazolidinediones
(pharmacology, therapeutic use)
|